Mitochondrial Peptides: An Overview of the Research on MOTS-c, Humanin, and SS-31

What Are Mitochondrial Peptides?

Mitochondria are often described as the powerhouses of the cell, but their role in cellular signaling extends well beyond ATP synthesis. Over the past two decades, researchers have identified a class of small peptides encoded directly within the mitochondrial genome — sequences inside open reading frames (ORFs) that were long overlooked as non-coding. These molecules, collectively termed mitochondria-derived peptides (MDPs), have emerged as an active area of preclinical investigation. The evidence base is largely preclinical — derived from cell-culture experiments and animal models — and safety and efficacy in humans has not been established.

For a broader grounding in peptide science, see our overview of what a peptide is and the companion article on research peptides explained.

The Mitochondrial Genome as a Peptide Source

The human mitochondrial genome is compact — roughly 16,569 base pairs encoding 13 proteins, 22 tRNAs, and 2 rRNAs. For decades, the 16S rRNA locus was considered purely structural. Research published in the early 2000s challenged that assumption by demonstrating that short ORFs within the 16S rRNA region encode small, biologically active peptides.

The first identified member of this family was Humanin (HN), discovered in a functional screen of cDNA libraries. Shortly after, MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) was identified in the 12S rRNA region. More recently, SHLP1–6 (Small Humanin-Like Peptides) were characterized as a subfamily of the humanin family. A structurally distinct mitochondria-targeting peptide, SS-31 (Elamipretide), is not encoded by the mitochondrial genome but is designed to concentrate in the inner mitochondrial membrane — it is included in mitochondrial peptide discussions because of its mechanistic focus on mitochondrial function.

"The discovery that the mitochondrial genome encodes bioactive peptides beyond its canonical 13 proteins fundamentally expands our understanding of mitochondrial communication with the rest of the cell."

Key Mitochondrial Peptides in Preclinical Research

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded in the 12S rRNA region of the mitochondrial genome. In preclinical models, researchers have investigated its involvement in metabolic regulation. Animal studies have examined MOTS-c in the context of insulin sensitivity, glucose homeostasis, and skeletal muscle function. Investigators have reported that MOTS-c can translocate to the nucleus under cellular stress conditions, where it appears to modulate gene expression related to oxidative stress responses. Research in rodent models has suggested associations with metabolic phenotypes, though mechanistic understanding remains incomplete. For a dedicated deep-dive, see our MOTS-c research overview.

Humanin

Humanin is a 21-amino-acid peptide first identified through its apparent cytoprotective effects in neuronal cell models. Subsequent preclinical studies have explored its potential roles in apoptosis inhibition, insulin signaling, and cellular stress responses. In animal models, circulating humanin levels have been reported to decline with age, prompting researchers to investigate its relationship to age-associated phenotypes. Our dedicated Humanin research overview covers the preclinical literature in greater depth.

SS-31 (Elamipretide)

SS-31 is a synthetic, tetrapeptide compound designed with an alternating aromatic-cationic motif that allows it to accumulate at the inner mitochondrial membrane. Preclinical research has focused on its interactions with cardiolipin — a phospholipid critical to the inner membrane's structural integrity and to the function of electron transport chain complexes. In animal models, researchers have investigated SS-31 in the context of ischemia-reperfusion, cardiac function, and age-related mitochondrial dysfunction. It has reached clinical trials for certain cardiovascular indications, though it remains investigational. For more detail, see our SS-31 / Elamipretide research overview.

SHLP2 and Other Family Members

The SHLP subfamily (SHLP1–6) shares structural homology with humanin and is encoded by overlapping ORFs in the 16S rRNA region. SHLP2 and SHLP3 have attracted particular attention in preclinical studies examining mitochondrial membrane potential and apoptotic signaling in cell culture models. Research in this subfamily is at an earlier stage than for humanin or MOTS-c, and findings should be considered highly preliminary.

Proposed Mechanisms Under Investigation

A central question in mitochondrial peptide research is how these molecules exert their reported effects. Several mechanisms have been proposed and are under active investigation in preclinical settings:

Peptide	Proposed Mechanism (Preclinical)	Primary Model Systems
MOTS-c	AMPK activation; nuclear translocation under stress; regulation of the folate cycle and methionine metabolism	Rodent metabolic models, cell culture
Humanin	FPRL1/CXCR4 receptor binding; Bax inhibition; STAT3 pathway modulation	Neuronal cell lines, rodent aging models
SS-31	Cardiolipin binding; stabilization of cristae architecture; reduction of electron leak at Complex I/III	Cardiac ischemia models, aged rodents
SHLP2	Mitochondrial membrane potential support; anti-apoptotic signaling	Cell culture (in vitro)

It bears emphasis that proposed mechanisms derived from cell-culture or animal experiments frequently do not translate directly to human biology. The distinction between in vitro and in vivo research is critically important when interpreting these findings.

Mitochondrial Peptides and Metabolic Research

One of the more active research threads concerns the relationship between mitochondrial peptides and metabolic regulation. MOTS-c has been studied alongside pathways relevant to insulin resistance and glucose uptake in skeletal muscle cells. Some investigators have framed MDPs as a form of mitochondrial-to-nuclear communication — an "inter-organellar signaling" system that allows mitochondria to relay their functional state to the rest of the cell.

This framing connects mitochondrial peptide research to the broader field of metabolic research, including investigations into NAD metabolism. Readers interested in that intersection may find our article on what is NAD a useful complement. Researchers have also examined whether mitochondrial peptide signaling intersects with sirtuin and AMPK pathways, though the picture remains preliminary in animal and cell-culture models.

Purity, Quality, and Research Considerations

For laboratory investigators working with mitochondrial peptides, compound quality is a critical variable. Synthesis purity directly affects the interpretability of experimental results, and researchers should verify HPLC chromatograms and mass spectrometry data before using any research compound. Our guides on understanding peptide purity and how to read a Certificate of Analysis walk through the key metrics. EVO Labs Research publishes third-party purity data for its compounds — researchers can view the Certificate of Analysis for any peptide in the catalog.

Lyophilized mitochondrial peptides are sensitive to moisture and repeated freeze-thaw cycles. Research-grade handling guidance is covered in our articles on peptide storage and stability and reconstituting research peptides.

Limitations and the State of the Evidence

The preclinical literature on mitochondrial peptides is growing but remains early-stage by clinical standards. Several important limitations bear highlighting for any researcher evaluating this field:

• Most data are in vitro or rodent-based. Cell-culture findings establish mechanistic hypotheses; animal data provide physiological context — but neither directly predicts human outcomes.
• Circulating levels and endogenous roles are incompletely understood. While researchers have detected MDPs in plasma and tissues, the physiological significance of circulating levels remains an active area of investigation.
• Receptor identification is incomplete. For several MDPs, the full complement of receptors and downstream signaling cascades has not been characterized.
• Dose-response relationships in animal models vary widely across studies, making direct comparisons between research groups challenging.
• Clinical translation is limited. SS-31 is the most clinically advanced MDP-adjacent compound, but even its clinical program is ongoing and investigational. For other MDPs, human data are sparse.

Researchers should approach this literature with appropriate scientific rigor, critically evaluating study design, model system relevance, and the degree to which findings have been replicated across independent groups. All compounds in this class are for laboratory research use only and are not approved for human administration.

Summary

Mitochondrial peptides — MOTS-c, Humanin, the SHLP family, and SS-31 — represent an active area of preclinical science. The central insight is that the mitochondrial genome encodes small signaling molecules beyond its 13 canonical proteins, and that these molecules participate in inter-organellar communication. Preclinical models have generated hypotheses about their roles in metabolic regulation and cellular stress responses, but robust human evidence is lacking and the field remains investigational. Researchers can explore the mitochondrial peptides research catalog at EVO Labs Research for research-grade material with third-party purity documentation.